DNMT1 and cancer: This issue raises concerns about the risk:benefit ratio with DNMT1 inhibitor use in human disease, which may be justifiable in cancer treatment, as currently permitted, but may be more difficult to justify in less life-threatening disorders involving epigenetic changes.